- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Wockhardt's novel antibiotic Miqnaf®'s pivotal Phase 3 study results for CABP published in THE LANCET Regional Health, validating its efficacy. This marks India's first new macrolide antibiotic in 30+ years, strengthening Wockhardt's innovation portfolio.